Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:

NCT ID: NCT02915315 Not yet recruiting - Hypertension Clinical Trials

Salt-sensitive Hypertension Study in Lantian County

SHSL
Start date: February 28, 2017
Phase: N/A
Study type: Observational

Essential hypertension is a complex trait which results from interaction between environmental factors and genetic factors. Our study aimed to detect the differential expression of LncRNAs and epigenetic changes such as DNA methylation associated with salt sensitive hypertension in human based on a chronic salt loading study conducted in Lantian county, China. Firstly, a chronic salt loading study will be conducted in a Chinese population to differentiate salt-sensitive and salt-resistant individuals. Second, LncRNAs and DNA methylation Chip analysis will be performed using samples collected from salt-sensitive and salt resistant individual, and the results will be analyzed by modern bioinformatics methods to seek for differential genetic markers. In addition, the investigators also try to examine the effects of chronic salt loading on BP, ambulatory BP, microalbuminuria and baPWV and other biochemical indexes. This project had great significance to reveal molecular genetics mechanism in the development of salt, salt-sensitive and hypertension.

NCT ID: NCT02901704 Not yet recruiting - Clinical trials for Primary Hypertension

Renal Denervation by Iberis MultiElectrode Renal Denervation System in Patients With Primary Hypertension

Iberis-HTN
Start date: December 2016
Phase: Phase 3
Study type: Interventional

The purpose of Iberis-HTN trial is to evaluate the safety and effectiveness of renal denervation in subjects with primary hypertension by using Iberis multielectrode renal denervation system

NCT ID: NCT02900729 Not yet recruiting - Hypertension Clinical Trials

Randomized Controlled Trial of Renal Denervation for Resistant Hypertension

Start date: October 2016
Phase: Phase 3
Study type: Interventional

Hypertension represents a significant global public health problem, contributing to vascular and renal morbidity, cardiovascular mortality, and economic burden. For a mostly asymptomatic disease, there is a huge challenge to maintain a good adherence and longtime persistence of drug use so as to adequately control it. Even so, a significant proportion of patients will develop resistant hypertension. In recent years, renal denervation has been argued as an effective means to address blood pressure problem in several non-Chinese clinical trials. The technique is to deliver low level radiofrequency energy through the renal artery wall to target the sympathetic nervous system and then modulate blood pressure. Shanghai WiseGain Medical Devices Co., LTD has developed the WiseGo Catheter System, which is an irrigated radiofrequency ablation Catheter. With this Catheter, it is expected to improve blood pressure status among patients with resistant hypertension failing polypharmacy. The purpose of this randomized control trial is to obtain an assessment of the efficacy and safety of WiseGo renal denervation technique in the presence of three standard antihypertensive medications in Chinese patients.

NCT ID: NCT02894723 Not yet recruiting - Hypertension Clinical Trials

L-arginine Treatment in Mild Hypertension

LAHN
Start date: September 2016
Phase: Phase 4
Study type: Interventional

Essential Hypertension is characterized by endothelial dysfunction due to reduced nitric oxide (NO) bioavailability. Impairment in nitric oxide-mediated vasodilatation in human brachial, coronary, and renal arteries has been demonstrated in patients with essential hypertension. Administration of L-arginine, a NO substrate yeld controversial results. The purpose of the present study, double blind and matched for age, sex and body mass index (BMI), is to assess the efficacy of L-arginine treatment on blood pressure (BP) control and arterial stiffness in patients with stage1 hypertension.

NCT ID: NCT02814734 Not yet recruiting - Clinical trials for Intra-Abdominal Hypertension

Abdominal Compartment Syndrome : Diagnostic and Prognostic Value of CT Findings - a Prospective Study

SCANAPIV
Start date: July 2016
Phase: N/A
Study type: Observational

Abdominal Compartment Syndrome (ACS) is a well known condition occuring in critically ill patients in intensive care units. This syndrome features a sustained intra abdominal hypertension (IAH) above 20 mmHg and a multiple organ failure due to the raise of the intra abdominal pressure. Several reviews described CT findings linked to these conditions, but most of them suffer an insufficient statistical method. Furthermore, the main CT feature described as specific in ACS, Round Belly Sign (RBS), has been highly debated since. This study is aimed to evaluate, in a prospective way, the diagnostic and prognostic value of CT findings in abdominal hypertension and abdominal compartment syndrome patients hosted in intensive care units, based on previous reviews and adding three new CT features described for the first time.

NCT ID: NCT02775539 Not yet recruiting - Heart Failure Clinical Trials

Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure

SPHERE-HF
Start date: June 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of mirabegron (a B3 adrenergic receptor agonist) in patients with pulmonary hypertension secondary to heart failure by conducting a randomized multicenter phase II placebo-controlled clinical trial.

NCT ID: NCT02710552 Not yet recruiting - Clinical trials for Arterial Hypertension

Low-dose Combination of Three Antihypertensive Drugs

3D
Start date: April 2016
Phase: Phase 4
Study type: Interventional

The aim of the study is to compare the efficacy and safety of low-dose combination of three antihypertensive drugs versus fixed high-dose combination of two antihypertensive drugs in arterial hypertension

NCT ID: NCT02710539 Not yet recruiting - Clinical trials for Arterial Hypertension

Once-daily Fixed Combination of Three Antihypertensive Drugs

ONE&ONLY
Start date: April 2016
Phase: Phase 4
Study type: Interventional

Randomized comparison of once-daily fixed combiNation versus free-drug combination of three antihypertensive agents in arterial hypertension

NCT ID: NCT02709031 Not yet recruiting - Diabetes Clinical Trials

Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium

CHAMP
Start date: June 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Cicletanine, which has been approved and launched for hypertension in France and Germany, has promise beyond hypertension in critically-unmet needs such as diabetes. It is evident from in vitro, animal and human studies that cicletanine's optimal dose in diabetes and other challenging, critically-unmet needs is likely to be higher than that for hypertension. Cicletanine's maximum tolerated dosage is not known, but the drug's dose-limiting effects are documented to be potassium loss and sodium loss from thiazide-type activity (one of the therapeutic mechanisms the drug is known to have); such thiazide-type losses are known to be reversed safely by magnesium. This trial explores the ability of magnesium to enhance cicletanine safety at higher doses in a trial involving patients with hypertension complicated by diabetes.

NCT ID: NCT02665858 Not yet recruiting - Clinical trials for Pediatric Idiopathic Intracranial Hypertension

OCT Imaging of Papilledema in Pediatric Idiopathic Intracranial Hypertension

Start date: February 2016
Phase: N/A
Study type: Interventional

Longitudinal clinical observation of optic nerve head, using slit lamp fundoscopy, guides therapy in pediatric idiopathic intracranial hypertension (IIH) patients; however, it remains a limited method of producing quantitative data in evaluating in patients with IIH. In this study we intend to compare, by using spectral domain optical coherence tomography (OCT), the mean retinal nerve fiber layer thickness and total retinal thickness (RNFLT/TRT) of the optic nerve of newly diagnosed IIH children to a control group. This will provide a quantitative measure for follow-up and treatment of this patient group.